Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases
Abstract
Penfluridol, isolated from an FDA-approved small-molecule drug library as an inhibitor of tumor necrosis factor α (TNFα)-stimulated NF-κB activation, is clinically used to treat chronic schizophrenia and related disorders. This study is aimed to investigate the therapeutic effect of penfluridol on TNFα-stimulated inflammatory autoimmune diseases, particularly inflammatory arthritis.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 19, 2022
- Source ID
- 10.1186/s13075-021-02713-6
Entities
People
- Aubryanna Hettinghouse
- Chen Zhang
- Chuan-ju Liu
- Lei Zhang
- Rong-han Liu
- Wen-yu Fu
- Ya-zhou Cui
- Yue-hong Chen
Organizations
- Computer Sciences Corporation